AbbVie's hepatitis C treatment helps 96 pct of patients in trial
Nov 18 (Reuters) - AbbVie Inc said a late-stage trial of its experimental oral hepatitis C treatment showed about 96 percent of patients had no detectable levels of the virus after 12 weeks.
The trial is being watched closely because of the potential of the treatment, 3D regimen, to obviate the need for the injectable drug interferon, which can have debilitating side effects.
The trial, named Sapphire-I, is the first of six late-stage trials testing AbbVie's interferon-free treatment.
- Israel pummels Gaza; Kerry steps up diplomatic push |
- Ukraine war crimes trials a step closer after Red Cross assessment
- South Korea ferry fugitive hid behind cabin wall, bags of cash at hand
- With sales sputtering, Apple's iPad looks to IBM alliance
- Five held in China food scandal probe, including head of Shanghai Husi Food